Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Gaia BioMedicine, a Japan-based cancer immuno-cellular therapeutics developer spun out of Kyushu University, has secured ¥1.3bn ($11.9m) in a series B round backed by Osaka University Venture Capital (OUVC), a vehicle for Osaka University. The round was led by financial services firm Mitsubishi UFJ subsidiary Mitsubishi UFJ Capital’s Life Science Fund 2 and also included financial services provider SBI subsidiary SBI Investment, pharmaceutical firm Hisamitsu Pharmaceutical and robotics Cyberdyne’s CEJ Capital unit’s CEJ Fund, in addition to its series A…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
